US Stock Insider Trading | Exagen Disclosed 2 Company Insider Transactions on March 16

K-LinePoet · 2026-03-24T14:30:36+00:00

Exagen disclosed insider trading activity by executive Jeffrey G. Black on March 16, 2026, including the purchase of 75,000 shares on March 12, as well as buy and sell transactions by other board members. The company focuses on improving diagnosis and treatment for patients with autoimmune diseases.

K-LinePoet

2026-03-24 14:30:36

Abstract generation in progress

On March 16, 2026, Exagen (XGN) disclosed two insider trading transactions. Executive Black Jeffrey G. purchased 75,000 shares on March 12, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 16, 2026	Executive	Black Jeffrey G.	February 27, 2026	Buy	1,511	3.08	4,649.35
March 16, 2026	Executive	Black Jeffrey G.	March 12, 2026	Buy	75,000	3.16	237,000
March 4, 2026	Director	ABALLI JOHN	March 3, 2026	Buy	2,535	3.08	7,800.20
March 4, 2026	Director	ABALLI JOHN	March 3, 2026	Sell	15,700	3.62	56,800
February 25, 2026	Director	ABALLI JOHN	February 24, 2026	Sell	11,400	3.61	41,300
February 25, 2026	Executive	Black Jeffrey G.	February 24, 2026	Sell	1,584	3.61	5,718.24
October 20, 2025	Director	ABALLI JOHN	October 16, 2025	Sell	33,800	11.82	375,600
September 4, 2025	Executive	Black Jeffrey G.	September 2, 2025	Sell	20,500	9.79	200,400
March 27, 2025	Shareholder with >10%	NMSIC Co-Investment Fund, L.P.	March 25, 2025	Sell	350,000	3.30	1,155,000
March 4, 2025	Director	ABALLI JOHN	February 28, 2025	Buy	8,621	2.47	21,300

【Company Information】

Exagen Inc. was founded in 2002. Exagen is dedicated to transforming patient care for those with frailty and chronic autoimmune diseases through timely diagnosis and optimized treatment interventions. The company’s goal is to enable rheumatologists to improve patient care by identifying, prognosticating, and monitoring complex autoimmune and autoimmune-related diseases (including SLE and rheumatoid arthritis or RA).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.